GB0817425D0 - Protease inhibitors - Google Patents

Protease inhibitors

Info

Publication number
GB0817425D0
GB0817425D0 GBGB0817425.2A GB0817425A GB0817425D0 GB 0817425 D0 GB0817425 D0 GB 0817425D0 GB 0817425 A GB0817425 A GB 0817425A GB 0817425 D0 GB0817425 D0 GB 0817425D0
Authority
GB
United Kingdom
Prior art keywords
protease inhibitors
protease
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0817425.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivir AB
Original Assignee
Medivir AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir AB filed Critical Medivir AB
Priority to GBGB0817425.2A priority Critical patent/GB0817425D0/en
Publication of GB0817425D0 publication Critical patent/GB0817425D0/en
Priority to PCT/EP2009/062407 priority patent/WO2010034789A1/en
Priority to AU2009295899A priority patent/AU2009295899A1/en
Priority to KR1020117009282A priority patent/KR20110059657A/en
Priority to CA2738025A priority patent/CA2738025A1/en
Priority to CN2009801480408A priority patent/CN102224155A/en
Priority to EA201170480A priority patent/EA201170480A1/en
Priority to JP2011528327A priority patent/JP2012503626A/en
Priority to EP09783392A priority patent/EP2350089A1/en
Priority to BRPI0919073A priority patent/BRPI0919073A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
GBGB0817425.2A 2008-09-24 2008-09-24 Protease inhibitors Ceased GB0817425D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB0817425.2A GB0817425D0 (en) 2008-09-24 2008-09-24 Protease inhibitors
BRPI0919073A BRPI0919073A2 (en) 2008-09-24 2009-09-24 protease inhibitors
CA2738025A CA2738025A1 (en) 2008-09-24 2009-09-24 Protease inhibitors
AU2009295899A AU2009295899A1 (en) 2008-09-24 2009-09-24 Protease inhibitors
KR1020117009282A KR20110059657A (en) 2008-09-24 2009-09-24 Protease inhibitors
PCT/EP2009/062407 WO2010034789A1 (en) 2008-09-24 2009-09-24 Protease inhibitors
CN2009801480408A CN102224155A (en) 2008-09-24 2009-09-24 Protease inhibitors
EA201170480A EA201170480A1 (en) 2008-09-24 2009-09-24 PROTEAS INHIBITORS
JP2011528327A JP2012503626A (en) 2008-09-24 2009-09-24 Protease inhibitor
EP09783392A EP2350089A1 (en) 2008-09-24 2009-09-24 Protease inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0817425.2A GB0817425D0 (en) 2008-09-24 2008-09-24 Protease inhibitors

Publications (1)

Publication Number Publication Date
GB0817425D0 true GB0817425D0 (en) 2008-10-29

Family

ID=39952075

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0817425.2A Ceased GB0817425D0 (en) 2008-09-24 2008-09-24 Protease inhibitors

Country Status (10)

Country Link
EP (1) EP2350089A1 (en)
JP (1) JP2012503626A (en)
KR (1) KR20110059657A (en)
CN (1) CN102224155A (en)
AU (1) AU2009295899A1 (en)
BR (1) BRPI0919073A2 (en)
CA (1) CA2738025A1 (en)
EA (1) EA201170480A1 (en)
GB (1) GB0817425D0 (en)
WO (1) WO2010034789A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201314503D0 (en) * 2013-08-13 2013-09-25 Medivir Ab Cysteine protease inhibitor salt
EP3946332A1 (en) 2019-04-05 2022-02-09 Université de Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
SE0400022D0 (en) * 2004-01-08 2004-01-08 Medivir Ab New compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
CA2738025A1 (en) 2010-04-01
CN102224155A (en) 2011-10-19
KR20110059657A (en) 2011-06-02
EA201170480A1 (en) 2011-12-30
EP2350089A1 (en) 2011-08-03
WO2010034789A1 (en) 2010-04-01
AU2009295899A1 (en) 2010-04-01
BRPI0919073A2 (en) 2016-03-15
JP2012503626A (en) 2012-02-09

Similar Documents

Publication Publication Date Title
HK1148739A1 (en) Hcv protease inhibitors hcv
HK1176601A1 (en) Ire-1a inhibitors ire-1a
ZA201100898B (en) Novel inhibitors
ZA201107636B (en) Protease inhibitors
EP2139883A4 (en) Hiv-1 protease inhibitors
EP2064177A4 (en) Protease inhibitors
EP2509956A4 (en) Cysteine protease inhibitors
EP2313426A4 (en) Novel protease inhibitors
EP2358692A4 (en) Cysteine protease inhibitors
ZA201102179B (en) Protease inhibitors
ZA201102837B (en) Phosphodiestarase inhibitors
EP2222662A4 (en) Kynurenine-aminotransferase inhibitors
GB0817429D0 (en) Enzyme inhibitors
GB0817425D0 (en) Protease inhibitors
GB0714941D0 (en) Inhibitors
GB0705212D0 (en) Protease inhibitors
GB0700369D0 (en) Protease inhibitors
GB0712176D0 (en) Protease inhibitors
GB0705213D0 (en) Protease inhibitors
GB0712543D0 (en) Protease inhibitors
GB0712544D0 (en) Protease inhibitors
GB0700378D0 (en) Protease inhibitors
GB201019387D0 (en) Inhibitors
GB0816125D0 (en) Novel inhibitors
AU2008904159A0 (en) Novel Protease Inhibitors

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)